A. Corpes-Comes

Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial.

J. Blanco, B. Trinité, L. Leal, 2022, medRxiv.